Novartis continued to build its case for secukinumab (AIN457), an IL-17A inhibitor in development for a range of inflammatory conditions.
Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.
Pathway Genomics had a busy week. The San Diego, CA-based genetic testing laboratory began by securing an investment from IBM that will also give it access to Watson, before going on to form a cancer research collaboration with a registry created by researchers from Memorial Sloan Kettering, Mayo Clinic, Dana-Farber and other organizations.
AstraZeneca has detailed the data from two of three studies of its late-stage combination program for lesinurad, a new drug for gout obtained in their $1.26 billion buyout of Ardea, which showed that the treatment hit the desired biomarker for blood levels of uric acid as promised--but added today that it failed to actually reduce the rate of painful flare-ups of the disease for patients in the study.
Bristol-Myers Squibb has pulled the covers off of impressive Phase III data on Opdivo (nivolumab), pointing to a 73% survival rate among advanced melanoma patients after one year of therapy compared to 42% for the long-used chemo drug dacarbazine.
Pet-drug developer Kindred Biosciences announced Thursday that its net loss in the third quarter was $6.1 million, up from $1.2 million in the same period a year ago, as research and development expenses grew to $3.8 million from $1 million.
Simply wishing away pain is not as far-fetched as you probably think, research from Swiss scientists shows. Using electroencephalography they were able to harness thought-specific brain waves to convert genes into proteins, or what's known as gene expression.
Boehringer Ingelheim is working with managed care giant WellPoint in an effort to use real-world data to inform the development of new treatments of atrial fibrillation, keeping up with a sweeping trend in cardiovascular R&D.
Puma Biotechnology's closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.
The U.K. government has set out its vision for how the National Health Service will transform into a tech-savvy, research-enabling organization by 2020. As part of the wide-reaching strategy, NHS England will create "test bed" sites at which bioinformatics approaches and other tools will be tested.